CD274 and neoplasm: An increasing number of studies have shown that tumor PD-L1 overexpression reflects an active tumor immune microenvironment and may be the premise behind the aforementioned PD-L1/PD-1 inhibitor therapy in which release of the brake indicates as more efficient than the reestablishment of an existing TIL tumoricidal capability de novo [44].